Company Announcements

Results analysis from Kepler Trust Intelligence

Source: RNS
RNS Number : 2055A
BH Macro Limited
22 September 2022

BH Macro (BHMG)



Results analysis from Kepler Trust Intelligence

Over the first half of the year to 30 June 2022 the BH Macro (BHMG) share price has increased significantly, despite (or indeed, perhaps, because of) the very difficult background for investment markets. Over the first half of 2022, the Net Asset Value ("NAV") per Sterling share in the Company increased by 15.53% and the NAV per US Dollar share increased by 14.11%.

BH Macro's Chairman, Richard Horlick said: "it is gratifying that your confidence in the Manager, and the new [management fee] arrangements, have been so well rewarded. Moreover, the shares, whilst generating very good absolute returns, have also provided even better returns when compared to most other investable asset classes."

Kepler View

In the interim statement, the Manager observes that going into the second half of the year, Europe faces profound economic challenges. Brevan Howard comment that the European Central Bank ("ECB") appears in an especially parlous position. They believe that the global macro environment is "complicated, challenging and changing at a fast pace".

In our view, this is precisely why investors have been attracted to BH Macro (BHMG), reflected in the premium to NAV which the shares have been trading on. BHMG has historically delivered positive returns in 17 of the 20 worst performing months for equities since IPO in 2007. Indeed, the strongest periods of performance have come at times of stress for equity and, more latterly, bond markets.

Currently the shares trade on a premium to NAV of 14.5%. Broadly, we would emphasise caution on the current level of premium for a closed-end fund. That said, over the long-term, Brevan Howard Master Fund Limited into which BHMG invests, has delivered clear diversification from risk assets over its lifetime.

In the words of BH Macro's Chairman, "the investment strategy of the Company should continue to provide diversifying returns against what remains a very difficult background".


Visit Kepler Trust Intelligence for more high quality independent investment trust research.

Important information

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.


Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.